In patients with muscle-invasive bladder cancer (MIBC) eligible for neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy, the addition of an adjuvant durvalumab (Imfinzi, AstraZeneca) increases overall survival (OS), according to a phase 3 randomized trial. The study results (abstract LBA5) were reported at the 2024 Congress of the European Society for Medical Oncology (ESMO), in Barcelona, Spain.
Overall survival was a secondary end point, but the improvement in OS